Race Oncology (ASX:RAC) has updated investors with market research commissioned to better understand the commercial potential for its lead asset, Zantrene, as a cardio-protective and anti-cancer agent in settings where anthracyclines are typically used.
Non-Executive chairman Dr John Cullity said, “This research, conducted by third-party life science strategy consulting firm, Triangle Insights Group is highly informative to Race’s understanding of Zantrene’s market potential.
"To complete this work, Triangle consulted with key stakeholders involved in the treatment and reimbursement chain - from cardio-oncologists to payors.
"The findings have been entirely useful, informing potential treatment scenarios for Zantrene in breast cancer, an area in which we have promising historical data. While the sample set was modest, this independent assessment provides a valid picture of the market and suggests a positive and wide-ranging financial opportunity.”
CEO and managing director Damian Clarke-Bruce added, “The Triangle Insights report indicates a major global commercial opportunity for Zantrene if proven to be a cardioprotective agent with anti-cancer activity in breast cancer.
"Physicians noted that cardioprotection from anthracycline-induced heart damage is a clear unmet need and that they would embrace treatment options for their patients. The peripheral (intravenous) formulation is critical for this specific opportunity in breast cancer and as we look toward partnerships or potential licencing agreements in the future.
"The team is working on the formulation and updates on its progress are expected during H1 CY23. By scope, this research project reviewed cardio oncology opportunities, and whilst breast cancer appears to be the obvious approach, the data is directional for further exploration in other cancer types.
"Being specific to the cardioprotection opportunity, this assessment was not scoped to review the other significant area of research and intellectual property potential for Zantrene = the pursuit of the FTO pathway. Investigating and understanding Zantrene’s ability to inhibit FTO remains a core component of our Three Pillar strategy and any relevant FTO-related market assessment may be additive to this research.”